The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of germline mutations on somatic alteration landscapes in BRCA-associated cancers.
 
Ali Arafa
No Relationships to Disclose
 
Catherine Handy Marshall
Consulting or Advisory Role - Bayer; Dendreon; McGraw-Hill Education; Obseva
Patents, Royalties, Other Intellectual Property - McGraw Hill - textbook royalties
Travel, Accommodations, Expenses - Bayer
 
Justin Hwang
Research Funding - Astrin Biosciences
 
Deborah Kay Armstrong
Consulting or Advisory Role - Johnson & Johnson/Janssen; Teon Therapeutics
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Pfizer (Inst); Syndax (Inst)
Other Relationship - AstraZeneca; AstraZeneca; AstraZeneca
 
William B. Isaacs
Honoraria - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Elizabeth Mauer
Employment - Tempus
Stock and Other Ownership Interests - Tempus
Research Funding - Tempus
Travel, Accommodations, Expenses - Tempus
 
Calvin Y. Chao
Employment - Exact Sciences; Tempus
Leadership - Exact Sciences; Tempus
Stock and Other Ownership Interests - Exact Sciences; Tempus
 
Emmanuel S. Antonarakis
Honoraria - AIkido Pharma; Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Celgene (Inst); ClinicalMind; Clovis Oncology (Inst); Constellation Pharmaceuticals; Curium Pharma; Dendreon (Inst); ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Orion; Sanofi; Tempus
Consulting or Advisory Role - AIkido Pharma; Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Orion; Sanofi; Tempus
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Celgene; Clovis Oncology; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi